Health Condition 1: I10-I16- Hypertensive diseases
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Torrent Pharmaceuticals Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult Male or female patients with newly diagnosed hypertension (BP more than 140/90 mmHg) 2. Patients diagnosed with hypertension and treated with Azelnidipine/telmisartan combination as initial line therapy
Exclusion criteria
Exclusion criteria: 1. Patients with current or past exposure to antihypertensive medications other than study drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Mean change in DBP & SBPTimepoint: from baseline at 12 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Proportion of patients achieving BP control (defined as mean seated SBP less than 130 mmHg and DBP less than 80 mmHg)Timepoint: at 12 2 weeks;2. Proportion of patients who sustained or improved on BP control achieved at 12 2 weeksTimepoint: over 24 2 weeks;3. Mean change in Heart RateTimepoint: from baseline at 12 2 weeks;4. Incidence of adverse eventsTimepoint: at any subsequent visit post baseline | — |
Countries
India
Contacts
Public ContactDr Mukesh Gabhane
Torrent Pharmaceuticals Ltd.
Outcome results
None listed